Skip to main content
SpringerLink
Log in

Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Mitogenic and growth inhibitory signals influence the activity of a family of cyclin dependent kinases (cdks). p27 is an important cdk inhibitor, acting in G1 to inhibit cyclin-cdks. As negative growth regulators, the cdk inhibitors may function as tumor suppressors. While the p16 gene plays a tumor suppressor role in cancers, p27 gene mutations have been identified only rarely. While high levels of p27 protein are expressed in normal human mammary epithelium, loss of p27 is frequent and is of independent prognostic significance in breast cancers. Low p27 is also a poor prognostic factor in colon, gastric, esophageal, lung, and prostate carcinomas, and enhanced proteasomal degradation may underlie loss of p27 in tumor cells. Loss of p27 has not been significantly correlated with tumor proliferation in a number of studies and may reflect alterations in differentiation and adhesion-dependent growth regulation germane to oncogenesis and tumor progression. Efforts to confirm the prognostic value of p27 are under way in a number of large breast cancer studies. These studies may also indicate whether loss of p27 in association with other traditional or novel markers has greater prognostic potential than each factor alone. p27 immunostaining is inexpensive and reliable and may become part of the routine histopathologic processing of tumors in the near future. Widespread application of p27 in prognostic testing will require greater uniformity in scoring techniques and determination of the cut off levels which distinguish individuals at high and low risk of cancer recurrence and death. Finally, the greatest utility of p27 may lie in the information it sheds on the biology of aberrant growth regulation in breast cancer and the potential to use this in the generation of novel therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Solomon MJ: Activation of the various cyclin/cdc2 proteins. Current Opinions in Cell Biology 5:180-186, 1993

    Google Scholar 

  2. Morgan DO: Principles of Cdk regulation. Nature 374:131-134, 1995

    Google Scholar 

  3. Sherr CJ: G1 phase progression: cycling on cue. Cell 79:551-555, 1994

    Google Scholar 

  4. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995

    Google Scholar 

  5. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland J: G1 control in mammalian cells. J Cell Sci Suppl 18:69-73, 1994

    Google Scholar 

  6. Murray AW: Creative blocks: cell cycle checkpoints and feedback controls. Nature 359:599-604, 1992

    Google Scholar 

  7. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543-546, 1992

    Google Scholar 

  8. El-Deiry WS, Tokino T, Velculescu VE, Levy D, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor supression. Cell 75:817-825, 1993

    Google Scholar 

  9. Gu Y, Turck CW, Morgan DO: Inhibition of Cdk2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707-710, 1993

    Google Scholar 

  10. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependant kinases. Cell 75:805-816, 1993

    Google Scholar 

  11. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90-98, 1994

    Google Scholar 

  12. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A: p27Kipl, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8:9-22, 1994

    Google Scholar 

  13. Polyak C, Lee M-H, Erdjument-Romage H, Koff A, Roberts J, Tempst P, Massague J: Cloning of p27-KIP1 a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994

    Google Scholar 

  14. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78:67-74, 1994

    Google Scholar 

  15. Lee M-H, Reynisdottir I, Massague J: Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with a unique domain structure and tissue distribution. Genes Dev 9:639-649, 1995

    Google Scholar 

  16. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ: p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-662, 1995

    Google Scholar 

  17. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olsen EN, Harper JW, Elledge SJ: p53-independent expression of p21CIP1 in muscle and other terminally differentiating cells. Science 267:1024-1028, 1995

    Google Scholar 

  18. Skapek SX, Rhee J, Spicer DB, Lassar AB: Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 267:1022-1024, 1995

    Google Scholar 

  19. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon G, Beach D, Lassar AB: Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267:1018-1022, 1995

    Google Scholar 

  20. Flores-Rosas H, Kelman Z, Dean FB, Pan Z, Harper JW, Elledge SJ, O'Donnell M, Hurwitz J: Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase δ holoenzyme. Proc Natl Acad Sci USA 91:8655-8659, 1994

    Google Scholar 

  21. Li R, Waga S, Hannon G, Beach D, Stillman B: Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537, 1994

    Google Scholar 

  22. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578, 1994

    Google Scholar 

  23. Dulic V, Kaufman WK, Wilson SJ, Tosty TD, Lees E, Harper JW, Elledge SJ, Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023, 1994

    Google Scholar 

  24. Petrocelli T, Poon R, Drucker D, Slingerland J, Rosen C: UVB irradiation induces p21Cip1/WAF1 and mediates G1 and S phase checkpoints. Oncogene 12:1387-1396, 1996

    Google Scholar 

  25. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J: Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-β. Science 260:536-539, 1993

    Google Scholar 

  26. Slingerland JM, Hengst L, Pan C-H, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol 14:3683-3694, 1994

    Google Scholar 

  27. Firpo EJ, Koff A, Solomon MJ, Roberts JM: Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol Cell Biol 14:4889-4901, 1994

    Google Scholar 

  28. Bernhard EJ, Maity A, Muschel RJ, McKenna WG: Effects of ionizing radiation on cell cycle progression. A review. Radiat Environ Biophys 34:79-83, 1995

    Google Scholar 

  29. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee M-H, Massague J, Crabtree GR, Roberts JM: Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372:570-573, 1994

    Google Scholar 

  30. Florenes VA, Bhattacharya N, Bani MR, Ben-David J, Kerbel RS, Slingerland JM: TGF-β mediated G1 arrest in a human melanoma cell line lacking p15-INK4B: evidence for cooperation between p21Cip1 and p27Kip1. Oncogene 13:2447-2547, 1996

    Google Scholar 

  31. Hall M, Bates S, Peters G: Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11:1581-1588, 1995

    Google Scholar 

  32. Poon R, Toyoshima H, Hunter T: Redistribution of the CDK inhibitor p27 between different cyclin-CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet light. Mol Biol Cell 6:1197-1213, 1995

    Google Scholar 

  33. Harper JW, Elledge S, Keyomarsi K, Dynlacht B, Tsai L-H, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, Wei N: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6:387-400, 1995

    Google Scholar 

  34. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261, 1994

    Google Scholar 

  35. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/Cdk4. Nature 366:704-707, 1993

    Google Scholar 

  36. Guan K-L, Jenkins CW, Li Y, Nichols MA, Wu Y, O'Keefe CL, Matera AG, Xiong Y: Growth suppression by p18, a p16INK4/MTS1 and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939-2952, 1994

    Google Scholar 

  37. Chan K-MF, Zhang J, Cheng L, Shapiro DN, Winoto A: Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16-INK4. Mol Cell Biol 15:2682-2688, 1995

    Google Scholar 

  38. Hirai H, Roussel MF, Kato J-Y, Ashmun RA, Sherr CJ: Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15:2672-2681, 1995

    Google Scholar 

  39. Sandhu C, Garbe J, Daksis J, Pan C-H, Bhattacharya N, Yaswen P, Koh J, Slingerland J, Stampfer MR: TGF-β stabilizes p15INK4B protein, increases p15-INK4B/cdk4 complexes and inhibits cyclin D1/cdk4 association in human mammary epithelial cells. Mol Cell Biol 17:2458-2467, 1997

    Google Scholar 

  40. Parry D, Bates S, Mann DJ, Peters G: Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 14:503-511, 1995

    Google Scholar 

  41. Cairns P, Mao L, Merlo A, Lee D, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415-417, 1994

    Google Scholar 

  42. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genetics 11:210-212, 1995

    Google Scholar 

  43. Hunter T, Pines J: Cyclins and cancer II: Cyclin D and cdk inhibitors come of age. Cell 79:573-582, 1994

    Google Scholar 

  44. Bates S, Peters G: Cyclin D1 as a cellular proto-oncogene. Semin Cancer Biol 6:73-82, 1995

    Google Scholar 

  45. Kanb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergmann W, Frants R, Goldhar DE, Green A, Mac-Lennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genetics 8:22-26, 1994

    Google Scholar 

  46. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin dependent kinase-4 inhibitor in multiple human cancers. Nature 368:753-756, 1994

    Google Scholar 

  47. Hengst L, Dulic V, Slingerland J, Lees E, Reed SI: A cell cycle regulated inhibitor of cyclin dependent kinases. Proc Natl Acad Sci USA 91:5291-5294, 1994

    Google Scholar 

  48. Kato J-Y, Matsuoka M, Polyak K, Massague J, Sherr C: Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 79:487-496, 1994

    Google Scholar 

  49. Casaccia-Bonnefil P, Tikoo R, Kiyokawa H, Friedrich V Jr, Chao MV, Koff A: Oligodendrocyte precursor differentiation is perturbed in the absence of the cyclin-dependent kinase inhibitor p27Kip1. Genes Dev 11:2335-2346, 1997

    Google Scholar 

  50. Durand B, Gao FB, Raff M: Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation. EMBO J 16:306-317, 1997

    Google Scholar 

  51. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R: Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 87:1069-1078, 1996

    Google Scholar 

  52. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 85:721-732, 1996

    Google Scholar 

  53. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K: Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720, 1996

    Google Scholar 

  54. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Polyak K, Firpo E, Tsai L, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and female sterility in p27Kip1-deficient mice. Cell 85:733-744, 1996

    Google Scholar 

  55. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685, 1995

    Google Scholar 

  56. Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science 271:1861-1864, 1996

    Google Scholar 

  57. Pagano M, Beer-Romero P, Glass S, Tam S, Theodoras A, Rolfe M, Draetta G: Targeting ubiquitin-mediated degradation for proliferation inhibitors. Seventh Pezcoller Symposium, Cancer Genes: Functional Aspects, 1995

  58. Aktas H, Cai H, Cooper GM: Ras links growth factor signalling to the cell cycle machinery via regulation of cyclin D1 and the cdk inhibitor p27Kip1. Mol Cell Biol 17:3850-3857, 1997

    Google Scholar 

  59. Takuwa N, Takuwa Y: Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 17:5348-5358, 1997

    Google Scholar 

  60. Kawada M, Yamagoe S, Murakami Y, Suzuki K, Mizuno S, Uehara Y: Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15:629-637, 1997

    Google Scholar 

  61. Alessandrini A, Chiaur DS, Erikson R, Pagano M: Regulation of the cyclin-depedent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11:342-345, 1997

    Google Scholar 

  62. Vlach J, Hennecke S, Amati B: Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1. EMBO J 16:5334-5344, 1997

    Google Scholar 

  63. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE: Cyclin E-CDK2 is a regulator of p27-Kip1. Genes Dev 11:1464-1478, 1997

    Google Scholar 

  64. Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B: Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J 15:6595-6604, 1996

    Google Scholar 

  65. Assoian RK: Anchorage-dependent cell cycle progression. J Cell Biol 136:1-3, 1997

    Google Scholar 

  66. Zhu X, Ohtsubo M, Bohmer RM, Roberts JM, Assoian RK: Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol 133:391-403, 1996

    Google Scholar 

  67. Fang FG, Watanabe N, Hunter T, Ruoslahti E: Dependence of cyclin E-cdk2 kinase activity on cell anchorage. Science 271:499-502, 1996

    Google Scholar 

  68. Radeva G, Petrocelli T, Behrend E, Leung-Hagesteijn C, Filmus J, Slingerland J, Dedhar S: Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J Biol Chem 272:13937-13944, 1997

    Google Scholar 

  69. St Croix B, Florenes V, Rak A, Flanagan JW, Bhattacharya N, Slingerland JM, Kerbel RS: Impact of the cyclin dependent kinase inhibitor p27Kip1 on adhesion-dependent resistance of tumor cells to anticancer agents. Nature Medicine 2:1204-1210, 1996

    Google Scholar 

  70. Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD, Vogelstein B: Assignment of human p27 Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 55:1206-1210, 1995

    Google Scholar 

  71. Ponce-Castaneda MV, Lee M-H, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J, Cordon-Cardo C: p27 Kip1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumours. Cancer Res 55:1211-1214, 1995

    Google Scholar 

  72. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilczynski S, Young YL, Bartram CR, Koeffler HP: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27 Kip1 in human malignancies. Cancer Res 55:2266-2269, 1995

    Google Scholar 

  73. Ferrando A, Balbin M, Pendas AM, Vizoso F, Velasco G, Lopez-Otin C: Mutational analysis of the human cyclin-dependent kinase inhibitor p27Kip1 in primary breast carcinomas. Human Genetics 97:91-94, 1996

    Google Scholar 

  74. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nature Medicine 3:227-230, 1997

    Google Scholar 

  75. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Medicine 3:222-225, 1997

    Google Scholar 

  76. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57:1259-1263, 1997

    Google Scholar 

  77. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, Lu X: High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94:6380-6385, 1997

    Google Scholar 

  78. Sgambato A, Zhang Y, Arber N, Hibshoosh H, Doki Y, Ciaparrone M, Santella RM, Cittadini A, Weinstein IB: Deregulated expression of p27Kip1 in human breast cancers. Clin Cancer Res 3:1879-1887, 1997

    Google Scholar 

  79. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Medicine 3:231-234, 1997

    Google Scholar 

  80. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM: Loss of cyclin dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58:542-548, 1998

    Google Scholar 

  81. Yang RM, Naitoh J, Philipson J, Wang H, deKernion JB, Loda M, Reiter RE: Low levels of p27 protein expression predict poor disease free survival in patients with pathological T2a-T3b adenocarcinoma of the prostate. J Urol 159:941-945, 1998

    Google Scholar 

  82. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T: p27 expression and gastric carcinoma. Nature Med 3:593, 1997

    Google Scholar 

  83. Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Research 58:1730-1735, 1998

    Google Scholar 

  84. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57:3381-3385, 1997

    Google Scholar 

  85. Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd F, Slingerland JM: Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a potential prognostic factor independent of ras. Submitted, 1998

  86. Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland J, Nesland JM, Holm R: Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: Inverse correlation with disease-free survival. Am J Pathol 153:305-312, 1998

    Google Scholar 

  87. Allessandrini A, Chiaur DS, Pagano M: Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11:342-345, 1997

    Google Scholar 

  88. Lloyd RV, Jin L, Qian X, Kulig E: Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 150:401-407, 1997

    Google Scholar 

  89. Jordan R, Bradley G, Slingerland JM: Reduced levels of the cell-cycle inhibitor p27KIP1 in epithelial dysplasia and carcinoma of the oral cavity. Submitted, Am J Pathol, 1998

  90. Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206-1219, 1993

    Google Scholar 

  91. Masood S: Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers. Surg Oncol Clin N Am 4:601-632, 1995

    Google Scholar 

  92. Jordan VC: "Studies on the estrogen receptor in breast cancer" — 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36:267-285, 1995

    Google Scholar 

  93. Muss HB, Thor AD, Berry DA, Kute T, Liu E, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1268, 1994

    Google Scholar 

  94. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-1056, 1992

    Google Scholar 

  95. Levin MN, Pritchard KI, Bramwell V, et al: A randomized trial of cyclophosphamide, Epirubicin, fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, fluorouracil in post menopausal women with node-negative breast cancer. J Clin Oncol, in press

Download references

Authors
  1. Sandrine Cariou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles Catzavelos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joyce M. Slingerland
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cariou, S., Catzavelos, C. & Slingerland, J.M. Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1. Breast Cancer Res Treat 52, 29–41 (1998). https://doi.org/10.1023/A:1006154900130

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006154900130

Search

Navigation